Overview

Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer.

Status:
Recruiting

Trial end date:
2021-03-01

Target enrollment:

Participant gender:

Summary

Randomized, Open-label, Single-dose, Two-sequence, Two-period, Crossover Bioequivalence Trial of Irinotecan Liposome Injection in Patients With Advanced Pancreatic Cancer.

Phase:

Phase 1

Details

Lead Sponsor:

CSPC Ouyi Pharmaceutical Co., Ltd.

Treatments:

Irinotecan